The journey to understanding incretin systems: Theory, practice and more theory

被引：7
|
作者：
Yabe, Daisuke [1 ,2 ,3 ]
Kuwata, Hitoshi [2 ,4 ,5 ]
Seino, Yutaka [2 ,4 ]
机构：
[1] Gifu Univ, Dept Endocrinol & Diabet, Grad Sch Med, Gifu, Japan
[2] Kansai Elect Power Med Res Inst, Yutaka Seino Distinguished Ctr Diabet Res, Osaka, Japan
[3] Kobe Univ, Div Mol & Metab Med, Dept Physiol & Cell Biol, Grad Sch Med, Kobe, Hyogo, Japan
[4] Kansai Elect Power Hosp, Ctr Diabet Metab & Endocrinol, Osaka, Japan
[5] Kansai Elect Power Hosp, Ctr Clin Nutr & Metab, Osaka, Japan
来源：
JOURNAL OF DIABETES INVESTIGATION | 2019年 / 10卷 / 05期
基金：
日本学术振兴会;
关键词：
DIABETES-MELLITUS; GUT MICROBIOTA;
D O I：
10.1111/jdi.13123
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Accumulating clinical data on incretin-based dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in the past decade have clearly confirmed their safety and efficacy as antidiabetes drugs. However, the journey to understand the incretin system and its role in health and disease continues.
引用
收藏
页码：1171 / 1173
页数：3
相关论文
共 50 条
12345